Visugromab (CTL-002) is a monoclonal antibody that targets and neutralises GDF-15. Visugromab exhibits synergistic anticancer activity with the anti-PD1 antibody Nivolumab, making it suitable for PD-1/PD-L1 recurrent/refractory metastatic solid tumours.
Purity:
98.80%
CAS Number:
[2556646-63-8]
Target:
PD-1/PD-L1|||TGF-beta/Smad
* VAT and and shipping costs not included. Errors and price changes excepted